Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gene therapy breakthroughs are exciting, but decoding the filings behind them is hard. Neurogene Inc鈥檚 reports blend dense scientific data, cash-flow forecasts, and FDA pathway details that can stretch beyond 200 pages. If you have ever wondered, 鈥淗ow do I find Neurogene Inc鈥檚 quarterly earnings report 10-Q filing?鈥� or needed Neurogene Inc insider trading Form 4 transactions before market moves, you know the challenge.
Stock Titan solves it. Our AI reads every submission the moment it hits EDGAR and creates plain-English summaries so you can start understanding Neurogene Inc SEC documents with AI instead of wrestling with technical jargon. Whether it鈥檚 an 8-K announcing a pivotal trial result or a proxy outlining executive compensation, the platform links each disclosure to practical questions like cash runway, partnership terms, and pipeline milestones.
Here鈥檚 what you gain in one place:
- AG真人官方-time alerts for Neurogene Inc Form 4 insider transactions real-time and executive stock sales.
- AI-powered extracts that turn the Neurogene Inc annual report 10-K simplified into an easy read, highlighting R&D spend and risk factors.
- Side-by-side comparisons of segment data from each Neurogene Inc quarterly earnings report 10-Q filing.
- Instant context when an Neurogene Inc 8-K material events explained filing discloses new clinical data or financing.
- Concise breakdowns of the Neurogene Inc proxy statement executive compensation so you can benchmark leadership incentives.
- Deep-dive modules offering Neurogene Inc earnings report filing analysis to gauge trial funding needs.
Investors tracking early-stage biotech risk can鈥檛 afford delays. Stock Titan delivers every NGNE filing, from S-1 shelf registrations to Neurogene Inc executive stock transactions Form 4, with AI commentary that turns complexity into clarity. Spend less time searching and more time making informed decisions.
Guidewire Software, Inc. (GWRE) 鈥� Form 144 filing dated 30 June 2025 discloses a proposed sale of 1,400 common shares by insider Mike Rosenbaum through Morgan Stanley Smith Barney. The planned transaction is valued at 鈮� US$0.33 million, based on the stated aggregate market value of US$331,646. With 84.2 million shares outstanding, the new sale represents roughly 0.002% of total shares.
The filing also details a consistent pattern of insider disposals during the prior three-month window. Between 31 March 2025 and 23 June 2025, Rosenbaum executed 21 separate trades totaling 24,125 shares, generating 鈮� US$5.33 million in gross proceeds. Adding the proposed sale raises cumulative disposals to 25,525 shares鈥攕till well below the 1% Rule 144 threshold and unlikely to create mechanical selling pressure in the secondary market.
While the dollar amounts are modest relative to Guidewire鈥檚 market capitalisation, the steady cadence of transactions may attract investor scrutiny over management鈥檚 near-term sentiment. The filing does not reference a Rule 10b5-1 trading plan; however, the signature page reiterates the standard representation that the insider is not in possession of undisclosed material adverse information.
No operational metrics, earnings data or corporate events are included in this filing. Consequently, the immediate financial impact on GWRE appears neutral; nevertheless, persistent insider selling can influence perception and warrants monitoring alongside forthcoming earnings releases and guidance.
FAQ
What is the current stock price of Neurogene (NGNE)?
What is the market cap of Neurogene (NGNE)?
What is the primary focus of Neurogene Inc?
How does the EXACT gene regulation technology work?
What differentiates Neurogene from other biotechnology companies?
In which therapeutic areas does Neurogene operate?
How does the company generate revenue?
What are key challenges faced by Neurogene in its development process?
Does Neurogene operate in a competitive landscape?
What is the significance of gene therapy in Neurogene鈥檚 strategy?
